menu search

RXRX / Recursion: Shaking Up The Biopharma Landscape With A Bold, Data-Driven Blueprint

Recursion: Shaking Up The Biopharma Landscape With A Bold, Data-Driven Blueprint
Recursion, a biopharma company, uses a data-driven approach to drug discovery, launching four clinical trials and planning a fifth in oncology. Recursion's software platform, the Recursion OS, is used to construct and navigate vast datasets, enabling the identification of patterns in the data that would be impossible for humans to detect. Despite significant revenue growth, Recursion's ability to generate revenue is still very hard to predict, and therefore the dilution risk looms large for shareholders. Read More
Posted: Jul 17 2023, 17:04
Author Name: Seeking Alpha
Views: 103121

RXRX News  

Recursion to Participate in Upcoming Investor Conference

By GlobeNewsWire
November 2, 2023

Recursion to Participate in Upcoming Investor Conference

SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize more_horizontal

Is Recursion Pharmaceuticals Stock a Buy Now?

By The Motley Fool
October 11, 2023

Is Recursion Pharmaceuticals Stock a Buy Now?

Recursion Pharmaceuticals is using a novel and promising approach to drug discovery. Its strategy has produced some candidates, but none yet seems clo more_horizontal

Is Recursion Pharmaceuticals Stock a Buy?

By The Motley Fool
September 30, 2023

Is Recursion Pharmaceuticals Stock a Buy?

It has multiple programs in its pipeline, which focuses on rare diseases and cancer. Its use of artificial intelligence made the stock a hot buy earli more_horizontal

Where Will Recursion Pharmaceuticals Be in 3 Years?

By The Motley Fool
September 11, 2023

Where Will Recursion Pharmaceuticals Be in 3 Years?

Recursion Pharmaceuticals has three different business segments that could grow. Its drug development pipeline will take the longest to yield sales. more_horizontal

Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data

By Market Watch
September 8, 2023

Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data

Amid fierce debate about prescription-drug prices and countless proposals to rein them in, there has been a point of widespread agreement: Those price more_horizontal

Recursion Pharmaceuticals stock gets boost after Nvidia results

By Market Watch
August 24, 2023

Recursion Pharmaceuticals stock gets boost after Nvidia results

Shares of Recursion Pharmaceuticals Inc. RXRX, +3.30% jumped more than 4% premarket on Thursday after chip giant Nvidia Corp. NVDA, +3.17% on Wednesda more_horizontal

3 Things About Recursion Pharmaceuticals That Smart Investors Know

By The Motley Fool
August 11, 2023

3 Things About Recursion Pharmaceuticals That Smart Investors Know

Recursion's pipeline is chasing a handful of relatively small opportunities. Its collaboration with Nvidia will take some time to pay off, assuming it more_horizontal

'We look like what the future of all biopharma companies will look like', says Recursion CEO Gibson

By CNBC Television
August 8, 2023

'We look like what the future of all biopharma companies will look like', says Recursion CEO Gibson

Chris Gibson, Recursion CEO, joins 'Closing Bell Overtime' to talk drug development, quarterly earnings, tech integration in pharmaceuticals and more. more_horizontal


Search within

Pages Search Results: